The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.

Acylated insulins wherein an acyl moiety is attached to the parent insulin and wherein the acyl moiety comprises repeating units of alkylene glycol containing amino acids and wherein there is only one lysine residue (K & Lys) in the parent insulin, having satisfactory properties when administered pulmonary.

The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Cyclic CRF antagonist peptides having improved properties of “drugability”. The peptides are 33 residues in length with a lactam bond between the residues in position 22 and 25; however, they may be N-terminally shortened by up to 3 residues.

To provide a diagnostic and therapeutic medicament, a bombesin analog peptide antagonist conjugate is provided which has general Formula (I), wherein A is a metal chelator comprising at least one radionuclide metal, B is a spacer linked to N-terminal of C or a covalent bond and C is a bombesin analog peptide antagonist having a sequence as claimed, where further x is an integer from 1 to 3 and n is an integer from 1 to 6. [A-(B)n]x—C (I)

Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds.

A method of producing a molecularly-imprinted material comprises synthesizing a peptide, oligosaccharide or oligonucleotide on a disposable surface modified support to produce a support surface-attached peptide, oligosaccharide or oligonucleotide, providing a selected monomer mixture, contacting the monomer mixture with the support surface-attached peptide, oligosaccharide or oligonucleotide, initiating polymerisation or at least one crosslinking reaction, dissolving or degrading the support surface-attached peptide, oligosaccharide or oligonucleotide and support, and obtaining molecularly imprinted material.

The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. FcγRIIIA), and in particular binding molecules that specifically bind the A form FcγRIII but do not bind to the B form of FcγRIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.

The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

The present invention relates to isolation of whey proteins and the preparation of a whey product and a whey isolate. In particular the present invention relates to the isolation of a β-lactoglobulin product and the isolation of an α-enriched whey protein isolate from whey obtained from an animal. The α-enriched whey protein isolate provided by the present invention is besides from being low in β-lactoglobulin also high in α-lactalbumin and immunoglobulin G.

The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.

The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.

The disclosure relates to anti-glial maturation factor beta (“GMF-B”) monoclonal antibodies (mAbs) and fragments thereof, as well as hybridoma lines that secrete antibodies or fragments. Therapeutic and diagnostic uses of such antibodies, including treatment and detection of cancer and dementia, and methods and kits for detecting cells or samples expressing GMF-B, including soluble GMF-B, are also encompassed.

The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues in the region of amino acids 100 to 125 of Bet v Ia or its corresponding region of the allergen having at least 40% identity to Bet v 1a.

Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive animation of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.

A composition having proanthocyanidin compounds having an average degree of polymerization of at least about 6. A method of administering to an immunosuppressed patient or a patient diagnosed with sepsis or septic shock a composition having a proanthocyanidin. A method of administering to a patient diagnosed with a gram negative bacterial infection a composition having proanthocyanidin compounds having an average degree of polymerization of at least about 6.

The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.

Methods for treating fatty liver disease, e.g., hepatic steatosis, using peptide fragments of the C-terminal end of glucagon-like peptide-1 (GLP-1), e.g., GLP-1(28-36).

The present invention relates to a cyclosporine emulsion containing: i) a cyclosporine ii) a natural oil (long chain triglyceride) iii) a phosphatidylcholine, iv) glycerol, v) a pharmaceutically tolerable alkali salt of a free fatty acid, vi) a medium chain triglyceride-oil vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment viii) water.

The present invention relates to gastrin derivatives comprising gastrin or an analogue or fragment thereof and a derivatisation group and therapeutic use thereof.

Provided are a support for affinity chromatography which has excellent alkali resistance, and a method for isolating immunoglobulin. A support for affinity chromatography, containing an immobilized protein ligand represented by the following formula (1): R—R2 (1) wherein R represents a polypeptide consisting of 4 to 30 amino acid residues that contains an amino acid sequence represented by ATK or ASK; and R2 represents a polypeptide consisting of 50 to 500 amino acid residues containing an immunoglobulin-binding domain consisting of an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, the partial sequence thereof, or an amino acid sequence having 70% or more identity to these sequences; with the proviso that a terminus at which R2 binds to R is C-terminus or N-terminus of the immunoglobulin-binding domain.

In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.

The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.

A method of forming a cross-linked protein structures includes preparing a solution of protein dissolved in a benign solvent and forming an intermediate protein structure from the solution. The intermediate protein structure can be cross-linked by providing for a specific ratio of chemical cross-linking agents to form the cross-linked protein structure. The solution can be prepared by adding a cross-linker of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) at a ratio of two-to-one of NHS to EDC to alcohol. PBS buffer (20×) can be added to the solution until the volume ratio of PBS buffer (20×) to alcohol is about one-to-one. About 16 percent by weight of protein can be dissolved in the solution. The solution can be electrospun to form an intermediate protein structure. After a period of time, the protein structure can be cross-linked to form the cross-linked protein structure.

The present application relates to antigen-binding proteins that are capable of binding to mammalian IgG. The frame-work regions of the antigen-binding proteins of the application preferably correspond to those of antibodies naturally that are devoid of light chains as may e.g. be found in camelids. The application further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, to the uses of such immunoadsorbent materials for the purification of mammalian IgG antibodies and for therapeutic apheresis.

The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.

Antigen binding proteins with T cell receptor-like paratopes, that is, with an antigen binding region specific for an human leukocyte antigen-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab')2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.

The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

The present invention relates to methods for forming dicarba bridges in organic compounds. This involves the use of a pair of complementary metathesisable groups on the organic compound, and subjecting the compound to cross-metathesis under microwave radiation conditions. In an alternative, the compounds contain a turn-inducing group between the pair of cross-metathesisable groups to facilitate the cross-metathesis.

A location aware user interface on a wireless handset is described. The location aware user interface comprises a location module configured to transmit a location message to a remote server via a network. The remote server is configured to determine whether the wireless handset is within a geofence. The user interface further comprises a display module configured to display at least one content item associated with the geofence. The user interface also comprises an input module configured to receive a user-created content item and transmit the received user-created content item to the remote server. The remote server is configured to associate the content item with the geofence in which the wireless handset is located.

Monitoring user activity on a mobile device is described. In one aspect, video content is received and played to a user of the mobile device. The monitoring activity detects an interruption of playback of the video content and determines an event associated with the interruption. The event is stored in the mobile device and communicated to a remote device.

A system that incorporates teachings of the present disclosure may include, for example, a set top box (STB) comprising a controller programmed to receive measurement data stored in a first wireless device serving as a portable monitoring gateway that collects subscriber collected data and store and analyze the measurement data at the STB using the received measurement data received from the first wireless device and optionally from a remote server or a local storage space having stored measurement data to provide analyzed results. Other embodiments are disclosed.

A system or method for inferring and selective display of visual and sound media content based on a pet(s)'s level of engagement or reactions to content displayed on any number of content display devices including, but not limited to, television screens, computer monitors, tablets, and cell phones and measured by a sensor. A content selection algorithm takes as input the sensor measurements and historical or pre-computed data to infer the pet(s)'s preference for content. A content modification algorithm interposes algorithmically computed shapes and sounds overlaid on top of the existing content to attract the attention of the pet(s) observing the display.

This broadcasting receiver includes a receiving portion receiving a broadcast signal, a determination portion determining whether or not a user to be subject to parental control of the broadcast signal has entered a prescribed range, and a control portion performing control of enabling parental control corresponding to a user determined to have entered the prescribed range in the case where the parental control corresponding to the user determined to have entered the prescribed range is disabled when the determination portion determines that the user to be subject to parental control has entered the prescribed range.

A method includes receiving first information identifying profile information associated with a customer, habit information associated with the customer's television viewing habits, or Internet usage information associated with the customer. The method also includes receiving preference information from the customer, wherein the preference information identifies advertisements or types of advertisements that the customer would like to view or would not like to view. The method further includes identifying advertisements based on the received first information and the received preference information, inserting, by a service provider, the identified advertisements in a television programming data stream and providing the identified advertisements to the customer.

An automatic content recognition (ACR)-enabled connected TV device may be associated with a paired device and the paired device may comprise a browser. The ACR-enabled connected TV device may be operable to enable, utilizing an ACR system, the browser to display, within a section of a browser window, interactive content related to certain content being presented by the ACR-enabled connected TV device. The ACR-enabled connected TV device may be operable to enable, utilizing the ACR system, a viewer to interact with the interactive content. The section of the browser window may be changed dynamically. The certain content may comprise an advertisement of a particular product and the interactive content may comprise a link to a website and/or other information related to the particular product. The certain content may comprise a program associated with a network and the interactive content may comprise information on polling questions related to the program.

A remote time shift buffer system with shadow tuning. The remote time shift buffer system includes a client in communication with a remote video recorder. The client tunes to a channel from a television signal source and sends the channel content to a television. When a channel change occurs at the client, the remote video recorder tunes to the same channel as the client and buffers the content. When a pause live television (PLTV) function is initiated, the remote video recorder generates an independent RTSB content stream using the buffered content. Once the RTSB content stream is available, the client switches inputs and displays the RTSB content stream from the remote video recorder. Manipulating the position within the RTSB content stream does not affect buffering of the live content. The remote time shift buffer system provides pause live television functionality with minimal loss of content.

A method and apparatus for detecting triggering events in a data stream, comprising extracting audio portions from the data stream, detecting a sequence of one or more Dual Tone Multiple Frequency (DTMF) signals representing the events from the extracted audio portions, and logging data representative of the sequence of DTMF signals into a database.

In one embodiment, a broadcast transmitter includes: a viewer information memory configured to store viewer information regarding a viewer who signs up for a subscription; a generator configured to generate individual information regarding a conditional access of a content including a first expiration time indicating an expiration time of the individual information and a second expiration time set independently of the first expiration time for each the viewer who signs up for the subscription based on the viewer information; and a transmitter configured to transmit a broadcast signal including the generated individual information.

Example apparatus and methods concern selectively accepting or rejecting content based on ratings identifier information included in the content. Example apparatus and methods facilitate identifying a content fragment (e.g., f-MP4 fragment) to be rejected based on an identifier located in the fragment rather than information located in some external source (e,g., Event Information Table (EIT)). One example method includes identifying a fragment based on a ratings identifier encoded as a universally unique identifier (UUID) in the fragment and then selectively accepting or rejecting the fragment based on the rating. Rather than rely only on a predicted start time, a predicted end time, a predicted source, and a pre determined coarse-grained rating, example apparatus and methods may be better prepared to account for unanticipated start times, ending times, schedule changes, and source changes, and may provide finer grained user control based on ratings carried in content.

User-based parental controls (UBPC) are provided. UBPC are provided to users according to a user profile associated with a specific user. Parental controls may be tailored to meet a parental control need according to each user. User profiles may be created by one or more administrative users and may include restrictions according to a TV, movie, application, or game rating system, specific channels, or specific programs. User profiles may be stored in a remote database allowing for various media content receiving and/or viewing devices to access the user profiles for applying parental control features according to a specific user profile. A user profile may be altered by one or more administrative users who may create an override access code which may allow the administrative user to manage other users' parental controls.

Sponsored-content may be placed based on images in video content. A first image in a frame of a video content item is identified. The first image is matched with a second stored image. A sponsored-content item to be presented is selected based on an association between the second stored image and the sponsored-content item.

A method includes receiving, at a multimedia device, a data stream representing multimedia content, the data stream comprising first timing information for the multimedia content, and metadata representing interactive event information associated with the multimedia content, the metadata comprising second timing information for the interactive event information. During the playback of the multimedia content, a first user interactive event is identified that is associated with a first time point in the playback of the multimedia content based on the interactive event information, and the first user interactive event is performed concurrent with the first time point in the playback of the multimedia content.

The present invention provides techniques relating to rich media advertising. Techniques are provided in which an advertiser-provided image-based component of an advertisement creative is matched with an advertiser-provided audio component of the advertisement creative. A rich media advertisement may be served that includes the image-based component and a synchronously presented audio component. Presentation of the rich media advertisement on a user computer may not require downloading or utilization of a video player.